- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
22 result(s) found for: Septic arthritis.
Displaying page 1 of 2.
EudraCT Number: 2017-001699-43 | Sponsor Protocol Number: BPR-CS-009 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ... | |||||||||||||
Medical condition: Complicated staphylococcus aureus bacteremia (cSAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015744-42 | Sponsor Protocol Number: NA | Start Date*: 2009-12-03 |
Sponsor Name:Oxford Radcliffe Hospitals Trust | ||
Full Title: Randomized open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment: Preliminary study in a single centre. | ||
Medical condition: Bone and joint infection including; o Osteomyelitis. o Septic arthritis. o Prosthetic joint associated infection o Orthopaedic device associated infection o Discitis/ epidural abscess | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003522-25 | Sponsor Protocol Number: APHP180672 | Start Date*: 2020-02-28 |
Sponsor Name:AP-HP | ||
Full Title: | ||
Medical condition: acute osteomyelitis of the child | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004465-15 | Sponsor Protocol Number: Study No. 957 | Start Date*: 2005-04-05 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: A multicentre, open, prospective study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT681 in patients wi... | |||||||||||||
Medical condition: primary immunodeficiency syndrome as congenital agammaglobulinaemia or hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiencies, Wiskott Aldrich syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003605-15 | Sponsor Protocol Number: IgPro20_3001 | Start Date*: 2015-02-26 | |||||||||||
Sponsor Name:CSL Behring AG | |||||||||||||
Full Title: A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID) | |||||||||||||
Medical condition: Primary Immune Deficiency (PID) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004441-32 | Sponsor Protocol Number: MSV-crio | Start Date*: 2013-03-06 | |||||||||||
Sponsor Name:Fundación Teknon | |||||||||||||
Full Title: Pilot clinical trial to determine the feasibility and safety of MSV * cryopreserved in the treatment of gonartrosis. * MSV = mesenchymal progenitor cells of expanded autologous bone marrow with GMP... | |||||||||||||
Medical condition: Patients diagnosed with gonarthrosis II, III and IV degrees of Kellgren and Lawrence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000620-34 | Sponsor Protocol Number: IGSC-1103 | Start Date*: 2013-08-05 | |||||||||||
Sponsor Name:LFB Biotechnologies | |||||||||||||
Full Title: A Multicentre Phase III Study on the Efficacy, Safety and Pharmacokinetics of LFB-IgSC in Patients with Primary Immunodeficiency (PID) Syndromes | |||||||||||||
Medical condition: Primary Immunofediciency (PID) syndromes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000934-31 | Sponsor Protocol Number: INN-TOP-005 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:Innocoll Pharmaceuticals Limited | |||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Pa... | |||||||||||||
Medical condition: Diabetic Patients with an Infected Foot Ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed) SK (Completed) NL (Completed) GB (Completed) PL (Completed) HU (Completed) DK (Completed) LV (Completed) LT (Completed) EE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000255-13 | Sponsor Protocol Number: 11-019 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Me... | |||||||||||||
Medical condition: Prophylaxis of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LV (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) AT (Completed) DK (Completed) CZ (Completed) BG (Completed) IT (Completed) FI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003652-52 | Sponsor Protocol Number: 991 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: An open label, prospective, multicenter study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT595 as repl... | |||||||||||||
Medical condition: Replacement therapy in patients with primary immunodeficiency disease (PID) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005679-18 | Sponsor Protocol Number: GMX04 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:Bio Products Laboratory Limited | |||||||||||||
Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents | |||||||||||||
Medical condition: Primary immunodeficiency diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2013-003877-87 | Sponsor Protocol Number: SCGAM-01 | Start Date*: 2014-03-12 |
Sponsor Name:Octapharma Pharmazeutika Prod.Ges.m.b.H | ||
Full Title: CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES | ||
Medical condition: Primary immunodeficiency | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) PL (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020167-20 | Sponsor Protocol Number: KB047 | Start Date*: 2010-10-19 | ||||||||||||||||
Sponsor Name:KEDRION | ||||||||||||||||||
Full Title: Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study | ||||||||||||||||||
Medical condition: Hypogammaglobulinaemia or agammaglobulinaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005321-51 | Sponsor Protocol Number: MSV_allo | Start Date*: 2012-04-13 | |||||||||||
Sponsor Name:Parque Científico de la Universidad de Valladolid | |||||||||||||
Full Title: Treatment of osteoarthritis with allogeneic mesenchymal cells (MSV *). | |||||||||||||
Medical condition: gonarthrosis (osteoarthritis) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004734-37 | Sponsor Protocol Number: NORM-01 | Start Date*: 2021-12-14 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Prod.Ges.m.b.H | |||||||||||||
Full Title: Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with p... | |||||||||||||
Medical condition: Primary Immunodeficiency Diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011434-10 | Sponsor Protocol Number: NGAM-01 | Start Date*: 2010-03-02 | ||||||||||||||||
Sponsor Name:OCTAPHARMA AG | ||||||||||||||||||
Full Title: CLINICAL STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF IMMUNOGLOBULIN INTRAVENOUS (HUMAN) 10% (NEWGAM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES | ||||||||||||||||||
Medical condition: Primary immunodeficiency diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001496-32 | Sponsor Protocol Number: KB070 | Start Date*: 2020-10-01 | |||||||||||
Sponsor Name:KEDRION S.P.A | |||||||||||||
Full Title: A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected... | |||||||||||||
Medical condition: Pediatric Patients Affected by Primary Immunodeficiency Disease. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000792-16 | Sponsor Protocol Number: GAMr-29 | Start Date*: 2012-06-14 | ||||||||||||||||
Sponsor Name:OCTAPHARMA AG | ||||||||||||||||||
Full Title: “CLINICAL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF OCTAGAM 5% IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES” | ||||||||||||||||||
Medical condition: primary immunodeficiency disease (PID) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023483-41 | Sponsor Protocol Number: I10E-0718 | Start Date*: 2011-03-01 | |||||||||||||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||||||||||||
Full Title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) | |||||||||||||||||||||||
Medical condition: a primary immunodeficiency as defined by the ESID and validated by a reference centre : • X-linked agammaglobulinemia (XLA) • Common variable immunodeficiency (CVID) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2010-019459-23 | Sponsor Protocol Number: 170903 | Start Date*: 2011-01-18 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: A CLINICAL STUDY OF IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) (IGSC), 20% FOR THE EVALUATION OF EFFICACY, SAFETY, AND PHARMACOKINETICS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES | |||||||||||||
Medical condition: Primary Immunodeficiency Diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) HU (Completed) SE (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
